Analyze Diet

Effects of large doses of phenylbutazone administration to horses.

Abstract: The effects of large doses of phenylbutazone were evaluated in clinically normal horses. The drug was given to 4 groups of 2 horses each at the rate of 30 mg/kg of body weight, orally, or 30, 15, or 8 mg/kg IV daily for up to 2 weeks. All horses became anorectic and depressed after 2 to 4 phenylbutazone treatments, and the horses given 15 or 30 mg/kg died on or between days 4 and 7 of treatment. A decrease in total blood neutrophil count occurred in all horses, and was associated with toxic left shift in horses given the 2 larger dosage schedules. The horses also had progressive increases in serum urea nitrogen, creatinine, and phosphorus concentrations, accompanied by decreasing serum calcium concentrations. There was a progressive decrease in total serum protein in all 8 horses. Gastrointestinal ulcerations, renal papillary necrosis, and vascular thromboses were the predominant postmortem findings.
Publication Date: 1983-05-01 PubMed ID: 6869982
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study evaluates the effects of large doses of the drug phenylbutazone on horses, finding that the high dosage levels led to detrimental health effects, including a decrease in blood neutrophil count, progressive increase in serum urea nitrogen, creatinine and phosphorus concentrations, as well as gastrointestinal ulcerations, renal papillary necrosis, and vascular thromboses.

Research Objective and Methodology

  • The primary aim of the research was to assess the potential health impacts of large doses of phenylbutazone administration on healthy horses.
  • The drug was administered to four groupings of two horses each. Three different dosages were tested – 30 mg/kg taken orally and intravenously (IV), and 15 or 8 mg/kg given IV.
  • The administered dosages were given daily, up to a duration of two weeks.

Research Findings: Health Impacts and Mortality

  • All horses involved in the study exhibited symptoms of anorexia and depression following two to four treatments with phenylbutazone.
  • Higher dosage levels proved to be fatal. Horses receiving 15 or 30 mg/kg doses died between the fourth and seventh days of the treatment.

Research Findings: Blood and Serum Changes

  • All horses saw a decrease in their total blood neutrophil count, a key part of the immune system, more significantly in horses given the two larger dosage schedules.
  • Audible increases in three constituents of the blood serum were observed – urea nitrogen, creatinine, and phosphorus, accompanied by declining serum calcium concentrations.
  • Moreover, there was an observed gradual decline in the total serum protein in all eight horses.

Research Findings: Postmortem Evaluations

  • The postmortem examination of the horses revealed that the primary causes of death were gastrointestinal ulcerations, renal papillary necrosis (damage to the kidney cells), and vascular thromboses (blood clots in the vessels).

Conclusion

  • In conclusion, the research demonstrates that high dosage levels of the drug phenylbutazone lead to detrimental health impacts in horses, affirming its potential toxic effects when administered in large quantities, including mortality.

Cite This Article

APA
MacKay RJ, French TW, Nguyen HT, Mayhew IG. (1983). Effects of large doses of phenylbutazone administration to horses. Am J Vet Res, 44(5), 774-780.

Publication

ISSN: 0002-9645
NlmUniqueID: 0375011
Country: United States
Language: English
Volume: 44
Issue: 5
Pages: 774-780

Researcher Affiliations

MacKay, R J
    French, T W
      Nguyen, H T
        Mayhew, I G

          MeSH Terms

          • Animals
          • Anti-Inflammatory Agents / adverse effects
          • Cat Diseases / chemically induced
          • Cats
          • Dog Diseases / chemically induced
          • Dogs
          • Female
          • Gastric Mucosa / drug effects
          • Gastrointestinal Diseases / chemically induced
          • Gastrointestinal Diseases / veterinary
          • Horse Diseases / chemically induced
          • Horses
          • Humans
          • Intestinal Mucosa / drug effects
          • Kidney Diseases / chemically induced
          • Kidney Diseases / veterinary
          • Kidney Papillary Necrosis / chemically induced
          • Kidney Papillary Necrosis / veterinary
          • Male
          • Neutropenia / chemically induced
          • Neutropenia / veterinary
          • Phenylbutazone / administration & dosage
          • Phenylbutazone / adverse effects
          • Rats
          • Rodent Diseases / chemically induced
          • Thrombophlebitis / chemically induced
          • Thrombophlebitis / veterinary
          • Ulcer / chemically induced
          • Ulcer / veterinary

          Citations

          This article has been cited 9 times.
          1. Tesena P, Vinijkumthorn R, Preuksathaporn T, Piyakul P, Chotikaprakal T, Sirireugwipas R, Wong-Aree K, Prapaiwan N. Evaluation of gastrointestinal tract lesions and serum malondialdehyde levels after repeated oral administration of phenylbutazone in horses. Vet Res Commun 2024 Aug;48(4):2343-2355.
            doi: 10.1007/s11259-024-10415-ypubmed: 38771448google scholar: lookup
          2. O'Brien M, Mochel JP, Kersh K, Wang C, Troy J. Phenylbutazone concentrations in synovial fluid following administration via intravenous regional limb perfusion in the forelimbs of six adult horses. Front Vet Sci 2023;10:1236976.
            doi: 10.3389/fvets.2023.1236976pubmed: 37691633google scholar: lookup
          3. Donnell JR, Frisbie DD. Use of firocoxib for the treatment of equine osteoarthritis. Vet Med (Auckl) 2014;5:159-168.
            doi: 10.2147/VMRR.S70207pubmed: 32670856google scholar: lookup
          4. Tesena P, Yingchutrakul Y, Roytrakul S, Wongtawan T, Angkanaporn K. Serum protein expression in Equine Glandular Gastric Disease (EGGD) induced by phenylbutazone. J Vet Med Sci 2019 Mar 20;81(3):418-424.
            doi: 10.1292/jvms.18-0679pubmed: 30674748google scholar: lookup
          5. Banse HE, MacLeod H, Crosby C, Windeyer MC. Prevalence of and risk factors for equine glandular and squamous gastric disease in polo horses. Can Vet J 2018 Aug;59(8):880-884.
            pubmed: 30104780
          6. Riesberg LA, Weed SA, McDonald TL, Eckerson JM, Drescher KM. Beyond muscles: The untapped potential of creatine. Int Immunopharmacol 2016 Aug;37:31-42.
            doi: 10.1016/j.intimp.2015.12.034pubmed: 26778152google scholar: lookup
          7. Galvin N, Dillon H, McGovern F. Right dorsal colitis in the horse: minireview and reports on three cases in Ireland. Ir Vet J 2004 Aug 1;57(8):467-73.
            doi: 10.1186/2046-0481-57-8-467pubmed: 21851661google scholar: lookup
          8. Orsini JA, Spencer PA. Effects of a histamine type 2 receptor antagonist, BMY-26539-01, on equine gastric acid secretion. Can J Vet Res 2001 Jan;65(1):55-9.
            pubmed: 11227196
          9. Carrick JB, Papich MG, Middleton DM, Naylor JM, Townsend HG. Clinical and pathological effects of flunixin meglumine administration to neonatal foals. Can J Vet Res 1989 Apr;53(2):195-201.
            pubmed: 2713784